- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07948213
Transformed B-cell Lymphoma : Clonal Evolution, Microenvironment Remodeling and Therapeutic Targets Discovery; Prospective Program (TYPHON-P)
The progression of small B-cell lymphomas toward a more aggressive histological form, specifically, diffuse large B-cell lymphoma (DLBCL) is a serious and most often fatal event. This process gives rise to several categories of scientific challenges :
- Anticipating this transformation through the early detection-while the disease is still in its indolent B-cell lymphoma stage-of biological markers that predict such a shift, particularly those that define tumor sub-clones at high risk of transformation.
- Identifying the specific event(s) that, within an ongoing and continuous process, trigger the definitive transition from the indolent B-cell lymphoma phase to the transformed B-cell lymphoma phase.
- Identifying the disrupted biological functions that drive treatment resistance in the transformed B-cell lymphoma stage, with the goal of defining new therapeutic targets.
Hypothesis :
- The aggressive transformation of indolent B-cell lymphomas results from an imbalance in the subclonal structure, driven by the evolution of a dominant subclone that undergoes aggressive transformation. This subclonal competition-occurring either spontaneously or under therapeutic pressure-is fueled by the acquisition and/or selection of specific molecular and epigenetic alterations, as well as favorable remodeling of the tumor microenvironment. Some of these changes are detectable as early as the indolent phase, offering the prospect of early detection, while others dictate the mechanisms of therapeutic resistance following transformation.
- Understanding the mechanisms of therapeutic resistance in transformed DLBCL could pave the way for the development of new, effective treatments. Furthermore, these insights could potentially be applied to resistant forms of de novo DLBCL-the most common category (40%) of B-cell lymphoma.
Our primary objective is to identify and validate the molecular, cellular, and microenvironmental alterations associated with therapeutic resistance in transformed B-cell lymphomas, and to investigate the presence of these mechanisms in resistant forms of de novo DLBCL.
Secondary objective 1. To understand the mechanisms underlying tumor evolution in each subtype of transformed B-cell lymphoma, with regard to both the characteristics of the tumor cell and its microenvironment.
Secondary objective 2. To develop cellular and animal models that mimic the transformed phase of indolent B-cell lymphomas.
Secondary objective 3. To identify biological characteristic, at the indolent B-cell lymphoma stag, that are predictive of aggressive transformation.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
- Annen: Identification of molecular and/or cellular signatures associated with the type of treatment response in patients with transformed B-cell lymphoma
- Annen: Identify, at the indolent/small-cell B-cell lymphoma stage, the biological characteristics that are predictive of aggressive transformation.
- Annen: investigate the existence of these mechanisms in resistant forms of de novo diffuse large B-cell lymphoma.
Detaljert beskrivelse
TYPHON-P is a regional, multicenter, longitudinal, and translational observational study based on the prospectivebuilding of a clinical-biological cohort and a centralized biobank, managed by the Lorraine Biological Resource Center and the Pathology Department of the Nancy University Hospital. The study will include patients with indolent B-cell lymphoma, transformed B-cell lymphoma, or de novo aggressive B-cell lymphoma, as well as patients for whom a non-tumor tissue sample is available to serve as a technical reference.
Clinical, biological, therapeutic, and outcome data will be collected from medical records, and residual tissue samples originally obtained for routine clinical care will be processed according to standardized pre-analytical procedures and stored for future analysis.
The program comprises three complementary analytical sub-studies:
(i) a longitudinal, paired study comparing samples from the same patient at both the indolent and transformed stages, with the aim of characterizing the mechanisms of transformation; (ii) an investigation into the association between biological characteristics and therapeutic response within various groups of transformed B-cell lymphomas, with an exploration of whether these associations can be extrapolated to de novo diffuse large B-cell lymphoma (the most common lymphoma subtype, 15% of which exhibit therapeutic resistance); (iii) a prognostic study using samples obtained at the indolent stage to identify biological characteristics associated with the subsequent risk of transformation.
Analyses will be conducted separately for each lymphoma subtype, with Richter transformation and transformed follicular lymphoma serving as the primary models, while rarer forms will be the subject of exploratory analyses. Initial discovery-phase analyses will primarily relie on available retrospective samples. The identified biological findings and signatures will subsequently be evaluated within the prospective collection, following a pre-specified validation strategy. Longitudinal follow-up, planned for a maximum duration of ten years, will serve to document disease transformation, treatments received, therapeutic response, progression, and survival. Prospective samples will undergo standardized processing in a fresh state-including, wherever possible, the preparation of viable cell suspensions-to facilitate multi-omic, single-cell, spatial, and functional analyses, as well as the development of patient-derived models.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Julien BROSÉUS, Professor
- Telefonnummer: +33 03 83 15 49 14
- E-post: j.broseus@chru-nancy.fr
Studiesteder
-
-
-
Nancy, Frankrike, 54000
- University Hospital of Nancy
-
Ta kontakt med:
- Mylène VAUTROT, Project manager
- Telefonnummer: +33 03 83 15 54 56
- E-post: m.vautrot@chru-nancy.fr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
The objective is to obtain a cohort of approximately 20 to 60 analyzable cases for each subtype of transformed B-cell lymphoma, enabling the exploration of molecular alterations associated with transformation, the study of mechanisms of therapeutic resistance, and the identification of biological signatures with theranostic relevance.
For technical and methodological reasons, a control group consisting of 20 non-tumor lymph node samples will be included in this study.
Recruitment objectives:
Recruitment target for the study group: 210 patients with transformed B-cell lymphoma
Recruitment targets for the 3 control subgroups:
- 210 patients for the group with untransformed indolent B-cell lymphoma
- 270 patients for the group with de novo diffuse large B-cell lymphoma
- 20 patients for the control group
Beskrivelse
Case groups: transformed B-cell lymphomas
Inclusion Criteria:
Patients who benefited from medical care at the University Hospital of Nancy or the Regional Hospital of Metz
-with a history of, or a current diagnosis of, one of the following five types of indolent B-cell lymphoma: CLL: chronic lymphocytic leukemia FL: follicular lymphoma MZL: marginal zone lymphoma LPL: lymphoplasmacytic lymphoma MCL: mantle cell lymphoma
Patients in whom an aggressive B-cell lymphoma is suspected and for whom a diagnostic workup (including a tumor biopsy with histopathological analysis) is underway:
Richter transformation (RT) Transformed follicular lymphoma (tFL) Transformed marginal zone lymphoma (tMZL) Transformed lymphoplasmacytic lymphoma (tLPL) Blastoid mantle cell lymphoma
- Cases subsequently confirmed as one of the following histological variants: DLBCL (Diffuse Large B-Cell Lymphoma), Hodgkin lymphoma, or blastoid variant
- Cases for which biological samples potentially containing tumor cells are available and confirmed to contain a significant proportion of tumor cells (> 30%)
- Patients for whom at least one of the following types of samples is available:
Circulating blood cells, plasma, serum, any sample of cerebrospinal fluid, pleural fluid, or peritoneal fluid, biopsies performed for the diagnosis and follow-up of the lymphoma, cells extracted from these biopsies
Exclusion Criteria:
- Samples that do not meet the required diagnostic criteria
- Samples that do not meet the quality criteria necessary for analysis
- Samples that lack sufficient tumor content/representativeness for the requirements and analytical standards involved
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Case group : Transformed B-cell lymphoma
Patients : - who benefited from medical care at the University Hospital of Nancy or the Regional Hospital of Metz Patients with a history of, or a current diagnosis of, one of the following five types of indolent B-cell lymphoma: CLL: chronic lymphocytic leukemia FL: follicular lymphoma MZL: marginal zone lymphoma LPL: lymphoplasmacytic lymphoma MCL: mantle cell lymphoma
|
Identification of molecular and/or cellular signatures associated with the type of treatment response in patients with transformed B-cell lymphoma-categorized as good responders (complete remission), partial responders, and non-responders (progression during treatment or primary refractory disease)-defined in a discovery cohort and subsequently validated in an independent cohort, with an assessment of effect size, reproducibility, and discriminative value. Performance of biological signatures, measured at the indolent stage, in predicting aggressive histological transformation during follow-up. This analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Biological associations will be characterized by their effect size, their statistical significance-following correction for multiple comparisons-and their reproducibility in a validation cohort. Presence/absence of these molecular and/or cellular signatures correlated with therapeutic response in de novo DLBCL, and correlation with therapeutic response within this group. |
|
De novo aggressive lymphoma group (primarily de novo DLBCL)
Patients: - who benefited from medical care at the Nancy University Hospital or the Metz-Thionville Regional Hospital. Patients in whom a de novo aggressive B-cell lymphoma (DLBCL, Hodgkin lymphoma, or a blastoid variant) is suspected, and for whom a diagnostic workup-including a tumor biopsy with histopathological analysis-is currently underway
|
Presence/absence of these molecular and/or cellular signatures correlated with therapeutic response in de novo DLBCL, and correlation with therapeutic response within this group. |
|
Indolent/small-cell non-transformed B-cell lymphomas group
Patients :
|
Performance of biological signatures, measured at the indolent stage, in predicting aggressive histological transformation during follow-up. This analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Biological associations will be characterized by their effect size, their statistical significance-following correction for multiple comparisons-and their reproducibility in a validation cohort. |
|
Non-tumor patient" control group / lymph node tissue and blood free of tumor cells
Patients:
|
Identification of molecular and/or cellular signatures associated with the type of treatment response in patients with transformed B-cell lymphoma-categorized as good responders (complete remission), partial responders, and non-responders (progression during treatment or primary refractory disease)-defined in a discovery cohort and subsequently validated in an independent cohort, with an assessment of effect size, reproducibility, and discriminative value. Performance of biological signatures, measured at the indolent stage, in predicting aggressive histological transformation during follow-up. This analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Biological associations will be characterized by their effect size, their statistical significance-following correction for multiple comparisons-and their reproducibility in a validation cohort. Presence/absence of these molecular and/or cellular signatures correlated with therapeutic response in de novo DLBCL, and correlation with therapeutic response within this group. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To identify and validate the molecular, cellular, and microenvironmental alterations associated with therapeutic resistance in transformed B-cell lymphomas, and to investigate the presence of these mechanisms in resistant forms of *de novo* DLBCLs
Tidsramme: 10 years
|
Outcome measure 1 : correlation between gene expression profiles at agressive stage, and response to treatment. Measurement : whole transcriptome profiling by RNA-sequencing Unit of measure : transcripts rates Outcome measure 2 : correlation between protein expression profiles at agressive stage, and response to treatment. Measurement : protein expression by liquid chromatography coupled with mass spectrometry Unit of measure : copy numbers for each protein Outcome measure 3 : correlation between tumor microenvironment, and response to treatment. Measurement : microenvironment profiling by flow cytometry Unit of measure : comparative enrichment for each immune cell subtype (CD4+ T-cells, CD8+ T-cells, macrophages) Treatment responses : good responders (complete remission), partial responders, and non-responders (progression during treatment or primary refractory disease). Signatures will be defined in a discovery cohort and subsequently confirmed in an independent cohort. |
10 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Identify, at the indolent/small-cell B-cell lymphoma stage, the biological characteristics that are predictive of aggressive transformation.
Tidsramme: 10 years
|
The analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Outcome measure 1 : correlation between gene expression profiles at indolent stage, and the occurence of agressive transformation. Measurement : whole transcriptome profiling Measurement tool : RNA-sequencing Unit of measure : transcripts rates Outcome measure 2 : correlation between DNA methylation profiles at indolent stage, and the occurence of agressive transformation. Measurement : whole methylome profiling Measurement tool : long read whole genome sequencing Unit of measure : methylation rates for 28 billion sites Outcome measure 3 : correlation between proteomic profiles at indolent stage, and the occurence of agressive transformation. Measurement : protein expression Measurement tool : liquid chromatography coupled with mass spectrometry Unit of measure : absolute numbers for each protein |
10 years
|
|
Develop cellular and animal models that mimic the transformed phase of indolent B-cell lymphomas.
Tidsramme: 10 years
|
Outcome measure 1 : gene expression profiles concordance between patient-derived experimental models and the original tumors. Measurement : whole transcriptome profiling by RNA-sequencing Unit of measure : rate of transcripts Outcome measure 2 : protein expression profiles concordance between patient-derived experimental models and the original tumors. Measurement : protein expression by liquid chromatography coupled with mass spectrometry Unit of measure : copy numbers for each protein Outcome measure 3 : tumor microenvironment profiles concordance between patient-derived experimental models and the original tumors. Measurement : microenvironment profiling by flow cytometry or immunohistochemistry Unit of measure : comparative enrichment for each immune cell subtype (CD4+ T-lymphocytes, CD8+ T-lymphocytes, CD25+ T-lymphocytes, macrophages) |
10 years
|
|
To understand the mechanisms underlying tumor evolution in each subtype of transformed B-cell lymphoma, with regard to both the characteristics of the tumor cell and its microenvironment.
Tidsramme: 10 years
|
Outcome measure 1 : modification of gene expressions in malignant cells between the indolent stage, and the agressive transformation. Measurement : gene expression Measurement tool : whole transcriptome sequencing (RNA-seq) Unit of measure : transcripts rates Outcome measure 2 : modification of protein expressions in malignant cells between the indolent stage, and the agressive transformation. Measurement : protein expression Measurement tool : liquid chromatography coupled with mass spectrometry Unit of measure : copy numbers for each protein Outcome measure 3 : modification of tumor microenvironment between the indolent stage, and the agressive transformation. Measurement : microenvironment profiling Measurement tool : flow cytometry Unit of measure : comparative enrichment for each immune cell subtype (CD4+ T-lymphocytes, CD8+ T-lymphocytes, CD25+ T-lymphocytes, macrophages) |
10 years
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Ten Hacken E, Sewastianik T, Yin S, Hoffmann GB, Gruber M, Clement K, Penter L, Redd RA, Ruthen N, Hergalant S, Sholokhova A, Fell G, Parry EM, Broseus J, Guieze R, Lucas F, Hernandez-Sanchez M, Baranowski K, Southard J, Joyal H, Billington L, Regis FFD, Witten E, Uduman M, Knisbacher BA, Li S, Lyu H, Vaisitti T, Deaglio S, Inghirami G, Feugier P, Stilgenbauer S, Tausch E, Davids MS, Getz G, Livak KJ, Bozic I, Neuberg DS, Carrasco RD, Wu CJ. In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities. Blood Cancer Discov. 2023 Mar 1;4(2):150-169. doi: 10.1158/2643-3230.BCD-22-0082.
- Broseus J, Hergalant S, Vogt J, Tausch E, Kreuz M, Mottok A, Schneider C, Dartigeas C, Roos-Weil D, Quinquenel A, Moulin C, Ott G, Blanchet O, Tomowiak C, Lazarian G, Rouyer P, Chteinberg E, Bernhart SH, Tournilhac O, Gauchotte G, Lomazzi S, Chapiro E, Nguyen-Khac F, Chery C, Davi F, Hunault M, Houlgatte R, Rosenwald A, Delmer A, Meyre D, Bene MC, Thieblemont C, Lichter P, Ammerpohl O, Gueant JL; ICGC MMML-Seq Consortium; Guieze R, Martin-Subero JI, Cymbalista F, Feugier P, Siebert R, Stilgenbauer S. Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis. Nat Commun. 2023 Jan 19;14(1):309. doi: 10.1038/s41467-022-34642-6.
- Parry EM, Lemvigh CK, Deng S, Dangle N, Ruthen N, Knisbacher BA, Broseus J, Hergalant S, Guieze R, Li S, Zhang W, Johnson C, Long JM, Yin S, Werner L, Anandappa A, Purroy N, Gohil S, Oliveira G, Bachireddy P, Shukla SA, Huang T, Khoury JD, Thakral B, Dickinson M, Tam C, Livak KJ, Getz G, Neuberg D, Feugier P, Kharchenko P, Wierda W, Olsen LR, Jain N, Wu CJ. ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer Cell. 2023 Oct 9;41(10):1803-1816.e8. doi: 10.1016/j.ccell.2023.08.013. Epub 2023 Sep 21.
- Parry EM, Leshchiner I, Guieze R, Johnson C, Tausch E, Parikh SA, Lemvigh C, Broseus J, Hergalant S, Messer C, Utro F, Levovitz C, Rhrissorrakrai K, Li L, Rosebrock D, Yin S, Deng S, Slowik K, Jacobs R, Huang T, Li S, Fell G, Redd R, Lin Z, Knisbacher BA, Livitz D, Schneider C, Ruthen N, Elagina L, Taylor-Weiner A, Persaud B, Martinez A, Fernandes SM, Purroy N, Anandappa AJ, Ma J, Hess J, Rassenti LZ, Kipps TJ, Jain N, Wierda W, Cymbalista F, Feugier P, Kay NE, Livak KJ, Danysh BP, Stewart C, Neuberg D, Davids MS, Brown JR, Parida L, Stilgenbauer S, Getz G, Wu CJ. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023 Jan;29(1):158-169. doi: 10.1038/s41591-022-02113-6. Epub 2023 Jan 9.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 2024PI145
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Anonymized samples and clinical data will be shared with companion research teams.
Material and/or data transfer agreements will be signed between the University hopital of Nancy (promoter) and the associated research teams.
IPD-delingstidsramme
Start date : inclusion date end date : end of the study (decembre 2036)
Tilgangskriterier for IPD-deling
Material and/or data transfer agreements will be signed between the University hopital of Nancy (promoter) and the associated research teams.
Data will be transfered with secured transfer protocols.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- ICF
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .